tiprankstipranks
Fresenius Medical Care AG & Co. KGaA (GB:0H9X)
LSE:0H9X

Fresenius Medical Care AG & Co. KGaA (0H9X) Price & Analysis

3 Followers

0H9X Stock Chart & Stats

€38.77
-€0.55(-1.25%)
At close: 4:00 PM EST
€38.77
-€0.55(-1.25%)

Bulls Say, Bears Say

Bulls Say
Revenue And EBIT ImprovementThe sharp top-line acceleration and wider operating margin indicate improved business execution and operating leverage. If sustained, this combination can strengthen earnings capacity across FME’s care delivery and dialysis products businesses.
Solid Cash GenerationStrong operating and free cash flow provide funding for maintenance investment, business needs, and shareholder distributions. Consistent conversion of earnings into cash supports financial resilience even if operating conditions become less favorable.
Moderate And Improving LeverageLower leverage than in prior years improves balance-sheet flexibility and reduces financing risk. This gives FME more capacity to support its global clinic and products operations while managing reimbursement, regulatory, and healthcare-demand pressures.
Bears Say
Mid-Level Net MarginsDespite stronger EBIT performance, limited net profitability leaves less earnings protection against reimbursement pressure, labor costs, manufacturing expenses, and other operating volatility. Margin improvement may therefore not fully translate into durable bottom-line growth.
Declining Equity CushionA shrinking equity base weakens financial capacity relative to the scale of operations and leaves less protection against future losses or restructuring needs. Although leverage is improving, the reduced cushion remains a structural balance-sheet constraint.
Softer Free Cash Flow MomentumStable cash generation is positive, but declining free cash flow momentum suggests that recent operating improvements have not yet produced sustained cash expansion. Continued softness could limit investment capacity or reduce flexibility for distributions and debt management.

Fresenius Medical Care AG & Co. KGaA News

0H9X FAQ

What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest share price was €34.60 and its highest was €47.81 in the past 12 months.
    What is Fresenius Medical Care AG & Co. KGaA’s market cap?
    Fresenius Medical Care AG & Co. KGaA’s market cap is €10.61B.
      When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
      Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Nov 03, 2026 which is in 62 days.
        How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
        Fresenius Medical Care AG & Co. KGaA released its earnings results on Aug 03, 2026. The company reported €1.123 earnings per share for the quarter, beating the consensus estimate of €1.068 by €0.055.
          Is Fresenius Medical Care AG & Co. KGaA overvalued?
          According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Fresenius Medical Care AG & Co. KGaA pay dividends?
            Fresenius Medical Care AG & Co. KGaA does not currently pay dividends.
            What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
            Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 1.05.
              How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
              Fresenius Medical Care AG & Co. KGaA has 268,564,640 shares outstanding.
                What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
                Fresenius Medical Care AG & Co. KGaA reported an EPS of €1.123 in its last earnings report, beating expectations of €1.068. Following the earnings report the stock price went up 1.599%.
                  Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
                  Currently, no hedge funds are holding shares in GB:0H9X
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Fresenius Medical Care AG & Co. KGaA Stock Smart Score

                    4
                    Neutral
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10
                    Learn more about TipRanks Smart Score

                    Company Description

                    Fresenius Medical Care AG & Co. KGaA

                    Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.

                    Fresenius Medical Care AG & Co. KGaA (0H9X) Earnings & Revenues

                    0H9X Stock 12 Month Forecast

                    Average Price Target

                    €37.56
                    ▼(-3.13% Downside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"€29","33":"€33","37":"€37","41":"€41","45":"€45"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44.65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€44.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.555,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€37.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,33,37,41,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.41,44.428461538461534,44.44692307692307,44.465384615384615,44.48384615384615,44.50230769230769,44.520769230769226,44.53923076923077,44.55769230769231,44.576153846153844,44.59461538461538,44.613076923076925,44.63153846153846,{"y":44.65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.41,43.8826923076923,43.355384615384615,42.82807692307692,42.30076923076923,41.77346153846154,41.246153846153845,40.71884615384615,40.19153846153846,39.66423076923077,39.136923076923075,38.60961538461538,38.082307692307694,{"y":37.555,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.41,43.301538461538456,42.19307692307692,41.08461538461538,39.97615384615384,38.86769230769231,37.75923076923077,36.65076923076923,35.54230769230769,34.433846153846154,33.325384615384614,32.21692307692308,31.10846153846154,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.623,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":42.353,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.546,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.777,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.42,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.901,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.641,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.208,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.208,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.054,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.32,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.23,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.41,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    CompuGroup Medical
                    Draegerwerk AG & Co. KGaA
                    Fresenius SE & Co. KGaA
                    MEDICLIN
                    RHON-KLINIKUM AG
                    Popular Stocks